BigHat Biosciences Completes First Stage of Research Collaboration with Amgen

SAN MATEO, Calif.--(BUSINESS WIRE)--BigHat Biosciences, Inc., a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, today announced the successful completion of the first stage of a previously undisclosed research collaboration and licensing agreement with Amgen applying BigHat’s platform for multi-objective optimization of a next-generation antibody. BigHat’s...

Click to view original post